Matoba, Yusuke http://orcid.org/0000-0002-2609-1778
Zarrella, Dominique T.
Pooladanda, Venkatesh
Azimi Mohammadabadi, Maryam
Kim, Eugene http://orcid.org/0000-0002-4815-5680
Kumar, Shaan
Xu, Mengyao
Qin, Xingping
Ray, Lauren J
Devins, Kyle M.
Kumar, Raj
Kononenko, Artem
Eisenhauer, Eric
Veillard, Irva E.
Yamagami, Wataru
Hill, Sarah J. http://orcid.org/0000-0002-9199-9459
Sarosiek, Kristopher A. http://orcid.org/0000-0002-4618-5085
Yeku, Oladapo O. http://orcid.org/0000-0002-6319-1647
Spriggs, David R.
Rueda, Bo R. http://orcid.org/0000-0001-9489-8699
Article History
Received: 23 September 2023
Revised: 12 February 2024
Accepted: 14 February 2024
First Online: 4 March 2024
Competing interests
: S.J.H. receives sponsored research support from Eli Lilly and Company and Merck, Sharp & Dohme Corporation and previously received support from AstraZeneca. None is directly related to this work. O.O.Y reports grants from Ascendis Pharma A/S, Avenge Bio, Inc., Immunocore Limited, Duality Biologics, Merck Sharp & Dohme Corporation, Pionyr Immunotherapeutics Inc., ProfoundBio, and the Department of Defense. Consulting fees from Celldex Therapeutics, GIMV NV, TigaTx Inc. Advisory board role at hC Bioscience. In addition, he has a patent pending for MUC16 Directed Antibodies for therapeutic applications, and a patent pending for Human Artificial Chromosomes for therapeutic applications. D.R.S. is a co-inventor of the MUC16ecto antibody 4H11 and the patent is held jointly by Memorial Sloan Kettering Cancer Center and Eureka Therapeutics. A patent application has been filed for the modified human 4H11 antibody. D.R.S. is also a co-inventor of a neutralizing anti-Gal3 antibody. B.R.R. reports serving on the advisory board for VincenTech and received research funding from Novartis Institutes for BioMedical Research. Neither has a direct connection to the current research. All other authors declare no COI related to the present study.
: Patient samples: Paraffin blocks representing primary surgical cases from patients with a diagnosis of USC were retrieved from either the Massachusetts General Hospital (MGH) Department of Pathology archives and from the Vincent Center for Reproductive Biology (VCRB)-MGH Gyn Repository. The samples were collected from cases between in 1994 and 2014 based on availability and quality of the paraffin blocks, viable tumor and available clinical data. All diagnosis were verified. All samples were obtained under Institutional Review Board approved protocol (MGB022P003117 and DFHCC07-049). Patient-derived USC organoids (PDOs) were provided by Dr. Sarah Hill, Dana Farber Cancer Institute. All animal experiments were approved by the Massachusetts General Brigham Institution Animal Care and Use Committee and performed according to the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals (Protocol number: 2017N000236).